[go: up one dir, main page]

RU2358972C2 - Производные арилхиназолина, которые способствуют высвобождению паратиреоидного гормона - Google Patents

Производные арилхиназолина, которые способствуют высвобождению паратиреоидного гормона Download PDF

Info

Publication number
RU2358972C2
RU2358972C2 RU2005123329/04A RU2005123329A RU2358972C2 RU 2358972 C2 RU2358972 C2 RU 2358972C2 RU 2005123329/04 A RU2005123329/04 A RU 2005123329/04A RU 2005123329 A RU2005123329 A RU 2005123329A RU 2358972 C2 RU2358972 C2 RU 2358972C2
Authority
RU
Russia
Prior art keywords
quinazolin
isopropylphenyl
prop
propargyloxy
ylmethyl
Prior art date
Application number
RU2005123329/04A
Other languages
English (en)
Other versions
RU2005123329A (ru
Inventor
Эва АЛЬТМАНН (CH)
Эва АЛЬТМАНН
Рене БЕРЛИ (CH)
Рене БЕРЛИ
Марк ГЕРШПАХЕР (CH)
Марк Гершпахер
Жоанне РЕНО (CH)
Жоанне РЕНО
Свен ВАЙЛЕР (DE)
Свен Вайлер
Лео ВИДЛЕР (CH)
Лео Видлер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9950319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2358972(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2005123329A publication Critical patent/RU2005123329A/ru
Application granted granted Critical
Publication of RU2358972C2 publication Critical patent/RU2358972C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
    • C07C17/12—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms in the ring of aromatic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/44—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/25—Aminoacetonitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к новым соединениям формулы I
Figure 00000172
где R1, R2, R3 и Y совместно с остатком формулы I представляют собой соединения, выбранные из группы, указанной в формуле изобретения, или к их фармацевтически приемлемым и расщепляемым сложным эфирам, или к их кислотно-аддитивным солям, обладающим свойствами промотора высвобождения паратиреоидного гормона. Соединения могут быть использованы для приготовления лекарственного средства, обладающего свойствами антагониста к чувствительному к кальцию рецептору паращитовидной железы, для лечения заболеваний, опосредованных действием паратиреоидного гормона. 6 н. и 1 з.п. ф-лы.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
Figure 00000150
Figure 00000151
Figure 00000152
Figure 00000153
Figure 00000154
Figure 00000155
Figure 00000156
Figure 00000157
Figure 00000158
Figure 00000159
Figure 00000160
Figure 00000161
Figure 00000162
Figure 00000163
Figure 00000164
Figure 00000165
Figure 00000166
Figure 00000167
Figure 00000168
Figure 00000169
Figure 00000170
Figure 00000171

Claims (7)

1. Соединение формулы I
Figure 00000172
,
где заместители R1, R2, R3 и Y совместно с остатком формулы I представляют собой соединение, выбранное из группы следующих соединений:
4-(4-Изопропилфенил)-1-(3-метансульфонилбензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-[3-(2-метансульфинилэтокси)бензил]-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-[3-(2-метансульфонилэтокси)бензил]-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-[2-(2-метоксиэтил)-2Н-тетразол-5-илметил]-6-проп-2-инилокси-1Н-хиназолин-2-тион
4-(4-Изопропилфенил)-1-(3-метансульфинилбензил)-6-пронаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-пиридин-2-илметил-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-(4-[1,2,3]триазол-2-ил-бензил)-1Н-хиназолин-2-он
1-(3-Бромпропил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-пиридин-3-илметил-1Н-хиназолин-2-он
1-[2-(2-Гидроксиэтокси)бензил]-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-[3-(2-Гидроксиэтокси)тиофен-2-илметил]-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(3-Хлор-4-гидрокси-5-метоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(2-Этоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(3-Этоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(2-Гидрокси-6-метоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(1Н-Индол-4-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(4-Гидрокси-3-метоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(2-Гидрокси-4-метоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
Метиловый эфир
2-гидрокси-5-[4-(4-изопропилфенил)-2-оксо-6-проп-2-инилокси-2Н-хиназолин-1-илметил]бензойной кислоты
1-(3-Хлор-4-гидроксибензил)-4-(4-изопропилфенил)-6-проп-2-инил-окси-1Н-хиназолин-2-он
1-(2-Хлорбензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(4-Гидрокси-3,5-диметоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(2,5-Диметоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
Амид 4-[4-(4-изопропилфенил)-2-оксо-6-проп-2-инилокси-2Н-хиназолин-1-илметил]-1Н-индол-2-карбоновой кислоты
1-(2-Этилбутил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
{3-[4-(4-Изопропилфенил)-2-оксо-6-проп-2-инилокси-2Н-хиназолин-1-илметил]фенокси}уксусная кислота
1-(2,3-Диметоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(2,3-Дигидробензо[1,4]диоксин-6-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(4-оксо-4Н-хромен-3-илметил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(2-метилбутил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(2,6-Дихлорбензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(2,3-Дихлорбензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-(3-трифторметил-бензил)-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-(4-трифторметил-бензил)-1Н-хиназолин-2-он
1-(3-Этокси-4-гидроксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(3-фенилбутил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(3,4-Диэтоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(3-Фтор-4-метоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
{4-[4-(4-Изопропилфенил)-2-оксо-6-проп-2-инилокси-2Н-хиназолин-1-илметил]фенокси}уксусная кислота
4-(4-Изопропилфенил)-1-(4-метокси-2,3-диметилбензил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(4-Бензилоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(3-Гидрокси-6-метилпиридин-2-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
{2-[4-(4-Изопропилфенил)-2-оксо-6-проп-2-инилокси-2Н-хиназолин-1-илметил]-6-метоксифенокси}уксусная кислота
4-(4-Изопропилфенил)-1-(3-метоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(3,4-диметоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(4-метоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(3,5-диметоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(2,5-диэтоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(4-этокси-2-гидроксибензил)-6-пропаргил-окси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(2,4-диэтоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(2-метоксибензил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(4-этоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(3-изопропоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(2,4-диэтоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(4-Бром-3-метоксибензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(3-гидрокси-4-метоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(2-метоксиметоксибензил)-6-проп-2-инил-окси-1Н-хиназолин-2-он
1-(4-Бром-3-этоксибензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(4-Хлор-4-метоксибензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3-Хлор-4-этоксибензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3-Хлор-4,5-диметоксибензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(4-Хлор-3-метоксибензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3-Фторбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3,4-Дифторбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(4-Хлорбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(4-Фторбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3-Хлорбеизил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3-Бром-4-гидрокси-5-метоксибензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3-Бром-4-гидрокси-5-метоксибензил)-4-(4-изопропилфенил)-6-пропаргилокси-1H-хиназолин-2-он
1-(3-Бромбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3-Бром-4,5-диметоксибензил)-4-(4-изопропилфснил)-6-пропаргилпкси-1Н-хиназолин-2-он
1-(3,4-Дибромбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3,4-Дихлорбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(4-Метилбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3-Метилбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(4-Этилбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(3,4-Диметилбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-Циклопропилметил-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(2-Бромтиазол-5-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(4,5-Дихлортиофен-2-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(5-метилтиофен-2-илметил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-хинолин-2-илметил-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-[2-(2,6,6-триметилциклогекс-1-енил)этил]-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-пропаргилокси-1-(3,3,3-трифторпропил)-1Н-хиназолин-2-он
1-(3,3-Диметилбутил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(2,2-Диметилпент-4-енил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(3,5-Диметил-1-фенил-1Н-пиразол-4-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(5-Бромтиофен-2-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(5-Гидроксиметилфуран-2-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(2-Бутил-5-хлор-1Н-имидазол-4-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(6-метоксипиридин-3-илметил)-6-проп-2-инилокси-1Н-хиназолин-2-он
7-[4-(4-Изопропилфенил)-2-оксо-6-проп-2-инилокси-2Н-хиназолин-1-илметил]-1Н-индол-2-карбонитрил
1-(2,4-Диаминопиримидин-5-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(6-Гидроксиметилпиридин-2-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-(3,5-Ди-трет-бутил-4-гидроксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
трет-Бутиловый эфир
4-[4-(4-изопропилфенил)-2-оксо-6-проп-2-инилокси-2Н-хиназолин-1-илметил]-2,2-диметилоксазолидин-3-карбоновой кислоты
4-(4-Изопропилфенил)-1-(4-метиламино-2-метилсульфанил-пиримидин-5-илметил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-{4-[2-(метилпиридин-2-иламино)этокси]-бензил}-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(2-метилгекс-4-енил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-(4-пиразин-2-илбензил)-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(3-метилсульфанилпропил)-6-проп-2-инилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-тиофен-2-илметил-1Н-хиназолин-2-он
1-Бензил-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-тион
4-(4-Изопропилфенил)-1-(3-метансульфонилбензил)-6-пропаргилокси-1Н-хиназолин-2-тион
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-тиофен-2-илметил-1Н-хиназолин-2-тион
1-Бензил-4-(4-изопропилфенил)-6-метокси-1Н-хиназолин-2-тион
4-(4-Изопропилфенил)-1-[2-(2-метоксиэтокси)пиридин-3-илметил]-6-пропаргилокси-1Н-хиназолин-2-тион
1-Бензо[1,2,5]тиадиазол-5-илметил-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-тион
2-{3-[4-(4-Изопропилфенил)-6-проп-2-инилокси-2-тиоксо-2Н-хиназолин-1-илметил]феиокси}этиловый эфир уксусной кислоты
1-(2,3-Диметоксихиноксалин-6-илметил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин
1-[5-(2-Гидроксиэтокси)тиофеи-2-илметил]-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-тион
1-Изопропил-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-тион
1-Бензил-4-(4-циклопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Циклопропилфенил)-1-(3,3-Диметилбутил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Циклопропилфенил)-1-(3-этокси-4-метоксибензил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Циклопропилфенил)-1-изопропил-6-пропаргилокси-1Н-хиназолин-2-он
1-Бензил-4-(4-циклопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-тион
2-{3-[4-(4-Изопропилфенил)-2-оксо-6-пропаргилокси-2Н-хиназолин-1-илметил]фенокси}масляная кислота
2-{3-[4-(4-Изопропилфенил)-2-оксо-6-пропаргилокси-2Н-хиназолин-1-илметил]фенокси}-2-метилпропионовая кислота
4-(4-Изопропилфенил)-1-[2-(2-метоксиэтокси)пиридин-3-илметил]-6-проп-2-инилокси-1Н-хиназолин-2-он
1-[6-(2-гидроксиэтокси)пиридин-2-илметил]-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-она
1-[6-Хлорпиридин-3-илметил]-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(2-Гидроксипиридин-3-илметил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(5-метоксипиридин-2-илметил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(6-метилпиридин-2-илметил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(2-Хлорпиридин-4-илметил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
1-(2-Хлорпиридин-3-илметил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-{6-[2-(2-метоксиэтокси)этокси]пиридин-2-илметил}-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-[6-(2-метоксиэтокси)пиридин-2-илметил]-6-пропаргилокси-1Н-хиназолин-2-он
5-Аллил-1-бензил-6-гидрокси-4-(4-изопропилфенил)-1Н-хиназолин-2-он
5-Аллил-1-[3-(2-хлорэтокси)-4-метоксибензил]-6-гидрокси-4-(4-изопропилфенил)-1Н-хиназолин-2-он
5-Аллил-6-гидрокси-4-(4-изопропилфенил)-1-тиофен-2-илметил-1Н-хиназолин-2-он
5-Аллил-6-гидрокси-4-(4-изопропилфенил)-1-(3-метилсульфанилбутил)-1Н-хиназолин-2-он
5-Аллил-6-гидрокси-4-(4-изопропилфенил)-1-(1-метил-2-фенилэтил)-1Н-хиназолин-2-он
5-Аллил-6-гидрокси-4-(4-изопропилфенил)-1-пиридин-3-илметил-1Н-хиназолин-2-он
5-Аллил-6-гидрокси-1-(4-гидрокси-3-метоксибензил)-4-(4-изопропилфенил)-1Н-хиназолин-2-он
5-Аллил-6-гидрокси-1-[2-(2-гидроксиэтокси)бензил]-4-(4-изопропилфенил)-1Н-хиназолин-2-он
5-Аллил-6-гидрокси-1-[3-(2-гидроксиэтокси)бензил]-4-(4-изопропилфенил)-1Н-хиназолин-2-он
5-Аллил-1-(3,5-диметоксибензил)-6-гидрокси-4-(4-изопропил-фенил)-1Н-хиназолин-2-он
1-Бензил-6-гидрокси-4-(4-изопропилфенил)-5-пропил-1Н-хиназолин-2-он
6-Гидрокси-1-изобутил-4-(4-изопропилфенил)-5-пропил-1Н-хиназолин-2-он
1-[(3-(3,4-Диметоксифенил)пропил)]-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-1-(3-фенилпропил)-6-пропаргилокси-1Н-хиназолин-2-он
1-[2-(3,5-диметоксифенил)этил]-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-[2-Гидрокси-2-(2,4,6-триметилфенил)этил]-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он
1-[2-(3,5-Дифторфенил)-2-гидроксиэтил]-4-(4-изопропилфенил)-6-проп-2-инилокси-1H-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-[(Е)-2-(2,4,6-триметилфенил)винил]-1Н-хиназолин-2-он
4-(4-Изопропилфенил)-6-проп-2-инилокси-1-((Е)-стирил)-1Н-хиназолин-2-он
1-[(Е)-2-(3-Хлор-4-метоксифенил)винил]-4-(4-изопропилфенил)-6-проп-2-инилокси-1H-хиназолин-2-он
1-[(Е)-2-(3,5-Диметилфенил)винил]-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он;
или его фармацевтически приемлемый и расщепляемый сложный эфир или кислотно-аддитивная соль.
2. 1-(3-Этокси-4-метоксибензил)-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-он или его фармацевтически приемлемая кислотно-аддитивная соль.
3. 1-(4-Бромбензил)-4-(4-изопропилфенил)-6-пропаргилокси-1Н-хиназолин-2-он или его фармацевтически приемлемая кислотно-аддитивная соль.
4. 1-[3-(2-Гидроксиэтокси)бензил]-4-(4-изопропилфенил)-6-проп-2-инилокси-1Н-хиназолин-2-тион или его фармацевтически приемлемая кислотно-аддитивная соль.
5. Соединение по п.1 или его фармацевтически приемлемая кислотно-аддитивная соль для получения фармацевтического препарата, обладающего свойствами промотора высвобождения паратиреоидного гормона.
6. Фармацевтическая композиция, обладающая свойствами промотора высвобождения паратиреоидного гормона, включающая соединение по любому из пп.1-4 в смеси с фармацевтически приемлемым наполнителем, разбавителем или носителем.
7. Применение соединения по любому из пп.1-4 для приготовления лекарственного средства, обладающего антагонизмом к чувствительному к кальцию рецептору паращитовидной железы, для лечения заболеваний, опосредованных действием паратиреоидного гормона.
RU2005123329/04A 2002-12-23 2003-12-22 Производные арилхиназолина, которые способствуют высвобождению паратиреоидного гормона RU2358972C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0230015.0 2002-12-23
GBGB0230015.0A GB0230015D0 (en) 2002-12-23 2002-12-23 Organic compounds

Publications (2)

Publication Number Publication Date
RU2005123329A RU2005123329A (ru) 2006-03-10
RU2358972C2 true RU2358972C2 (ru) 2009-06-20

Family

ID=9950319

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005123329/04A RU2358972C2 (ru) 2002-12-23 2003-12-22 Производные арилхиназолина, которые способствуют высвобождению паратиреоидного гормона

Country Status (26)

Country Link
US (2) US7696216B2 (ru)
EP (2) EP1585521B8 (ru)
JP (2) JP4485956B2 (ru)
KR (2) KR20070097136A (ru)
CN (2) CN1732002A (ru)
AR (1) AR042650A1 (ru)
AT (1) ATE398450T1 (ru)
AU (1) AU2003296710B2 (ru)
BR (1) BR0316877A (ru)
CA (1) CA2509151C (ru)
DE (1) DE60321722D1 (ru)
EC (1) ECSP055888A (ru)
ES (1) ES2308041T3 (ru)
GB (1) GB0230015D0 (ru)
IL (1) IL169183A (ru)
MX (1) MXPA05006866A (ru)
MY (1) MY152921A (ru)
NO (1) NO331845B1 (ru)
NZ (1) NZ540849A (ru)
PE (1) PE20040971A1 (ru)
PL (1) PL378916A1 (ru)
PT (1) PT1585521E (ru)
RU (1) RU2358972C2 (ru)
TW (1) TWI333952B (ru)
WO (1) WO2004056365A2 (ru)
ZA (1) ZA200504386B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
GB0230015D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
EP1671961A4 (en) * 2003-09-17 2009-04-01 Sumitomo Chemical Co CINNAMOYL COMPOUND AND ITS USE
GB0516723D0 (en) * 2005-08-15 2005-09-21 Novartis Ag Organic compounds
WO2008041118A2 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
EP1956019A1 (en) * 2007-01-22 2008-08-13 Novartis AG Benzoquinazoline derivatives
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
EP2323997B1 (en) 2008-07-31 2017-09-06 Senomyx, Inc. Processes and intermediates for making sweet taste enhancers
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010136035A2 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2012069420A2 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
CN103228629A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 作为CaSR活性化合物的被取代的环戊基-氮杂苯类
EP3593648B1 (en) 2012-08-06 2021-07-14 Firmenich Incorporated Sweet flavor modifier
CN103848781B (zh) * 2012-11-30 2017-06-30 重庆华邦制药有限公司 高选择性氧化二羟甲基吡啶中一个羟甲基的方法
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
CN104387317B (zh) * 2014-11-27 2017-05-10 安徽星宇化工有限公司 一种6‑氯烟酸的制备方法及分离纯化方法
CN112703193A (zh) 2018-08-07 2021-04-23 弗门尼舍公司 5-取代的4-氨基-1H-苯并[c][1,2,6]噻二嗪2,2-二氧化物及其制剂和用途
WO2021029517A1 (en) * 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
CN113967249A (zh) * 2021-12-10 2022-01-25 深圳先进技术研究院 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用
CN116621719B (zh) * 2022-04-02 2024-01-30 南京工业大学 一种应用于制备聚氨酯的全生物基芳基二胺扩链剂的合成方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812257A (en) * 1972-04-07 1974-05-21 Sumitomo Chemical Co Uricosuric agent
SU517242A3 (ru) * 1970-12-08 1976-06-05 Сумитомо Кемикал Компани Лимитед (Фирма) Способ получени 2-( -монозамещенных амино)-фенилкетоновых производных
SU640663A3 (ru) * 1971-10-14 1978-12-30 Сумитомо Кемикал Компани Лимитед (Фирма) Способ получени производных нитрохиназолинона
CH612186A5 (en) * 1974-07-13 1979-07-13 Sumitomo Chemical Co Process for the preparation of 2(1H)-quinazolinone derivatives
SU900810A3 (ru) * 1977-09-06 1982-01-23 Сандос Аг (Фирма) Способ получени 4-арилхиназолин-2/1н/-онов
US4387223A (en) * 1975-12-11 1983-06-07 Sumitomo Chemical Company, Limited Process for preparing 2(1H)-quinazolinone derivatives
US5773663A (en) * 1996-05-01 1998-06-30 American Cyanamid Company Fungicidal methods, compounds and compositions containing benzophenones

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB181570A (en) 1921-05-07 1922-06-22 Malcolm Beresford Bennett Improvements in building blocks and in walls formed therewith
US3305553A (en) 1965-10-18 1967-02-21 Parke Davis & Co 2-aminoquinazoline derivatives
CH487902A (de) 1966-08-29 1970-03-31 Sandoz Ag Verfahren zur Herstellung von neuen Chinazolinonen
FR6001M (ru) 1966-12-02 1968-04-29
BG16442A3 (bg) 1967-10-30 1972-11-20 Max Denzer Метод за получаване на нови о-изопропиламинобензофенони
BG16042A3 (bg) * 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3712892A (en) 1969-08-02 1973-01-23 Sumitomo Chemical Co Quinazolinone derivatives
DE2137008A1 (de) * 1970-10-21 1972-04-27 Zellweger Uster Ag Verfahren und Vorrichtung zur automatischen Ablesung von Informationsträgern an Gegenständen
BE790804A (fr) 1971-11-18 1973-04-30 Sandoz Sa Procede de preparation de derives de la quinazoline
JPS5418269B2 (ru) 1972-07-20 1979-07-06
JPS555506B2 (ru) 1972-09-07 1980-02-07
US4067868A (en) 1973-04-17 1978-01-10 Sumitomo Chemical Company, Limited Production of quinazolinone compounds
JPS5046680A (ru) 1973-08-20 1975-04-25
US3923003A (en) 1974-05-06 1975-12-02 Southwire Co Production of flooded multistrand cable
JPS5251379A (en) * 1975-10-24 1977-04-25 Sumitomo Chem Co Ltd Preparation 3,4-dihydro-2(1h)-quinazoline derivates
CH625512A5 (ru) * 1976-12-13 1981-09-30 Sandoz Ag
US4171441A (en) 1977-09-06 1979-10-16 Sandoz, Inc. Preparation of quinazolin-2(1H)-ones
JPS55143959A (en) * 1979-04-26 1980-11-10 Shionogi & Co Ltd 2-acylbenzcyanamide derivative
JPS5795966A (en) 1980-12-04 1982-06-15 Sumitomo Chem Co Ltd Novel 2(1h)-quinazolinone derivative
JP3142638B2 (ja) * 1991-06-21 2001-03-07 三井化学株式会社 感熱記録材料およびフェノール化合物
DE69422450T2 (de) 1993-06-29 2000-06-08 Takeda Chemical Industries, Ltd. Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
HU228150B1 (en) * 1994-10-21 2012-12-28 Nps Pharma Inc Calcium receptor-active compounds, medicaments comprising them, and the use of said medicaments
CN1136547C (zh) 1995-08-22 2004-01-28 松下电器产业株式会社 光盘记录和／或重放装置及设定记录功率及清除功率的方法
JPH11514361A (ja) 1995-10-16 1999-12-07 藤沢薬品工業株式会社 Ｈ＋−ＡＴＰａｓｅとしての複素環式化合物
CA2190708A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
WO2002024683A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
DE10058347A1 (de) 2000-11-23 2002-06-13 Petra Bauersachs Konvergenz-Boxen-Set
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
GB0230015D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU517242A3 (ru) * 1970-12-08 1976-06-05 Сумитомо Кемикал Компани Лимитед (Фирма) Способ получени 2-( -монозамещенных амино)-фенилкетоновых производных
SU640663A3 (ru) * 1971-10-14 1978-12-30 Сумитомо Кемикал Компани Лимитед (Фирма) Способ получени производных нитрохиназолинона
US3812257A (en) * 1972-04-07 1974-05-21 Sumitomo Chemical Co Uricosuric agent
CH612186A5 (en) * 1974-07-13 1979-07-13 Sumitomo Chemical Co Process for the preparation of 2(1H)-quinazolinone derivatives
US4387223A (en) * 1975-12-11 1983-06-07 Sumitomo Chemical Company, Limited Process for preparing 2(1H)-quinazolinone derivatives
SU900810A3 (ru) * 1977-09-06 1982-01-23 Сандос Аг (Фирма) Способ получени 4-арилхиназолин-2/1н/-онов
US5773663A (en) * 1996-05-01 1998-06-30 American Cyanamid Company Fungicidal methods, compounds and compositions containing benzophenones

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chem. Abstr., 1981: 461773. *
On line! Chem. Abstr. 120: 244939, JAEDA MOUSA I. et al. "Synthesis of some novel 2(1H)-quinazulinones and 2-thioxo analogs from newly synthesized 1-acyl-3-alkoxyphenylureas and thioureas" J. of Chemical Technology and Biotechnology, 1993, 58 (4), 391-4). *
On Line! Chem. Abstr., 1982: 503745, MARDENTE SALVATORE et al. "GLC-ECD determination of 1(2-hydroxyethyl)-3-hydroxy-7-chloro-1,3-dihydro-5-(О-flourophenyl)-2H-1,4-benzodiazepin-2-one (SAS-643) in plasma and urine and indetification of its main biotransformation products" Therapeutic Drug Monitoring, 1981, 3 (4), 351-6. *

Also Published As

Publication number Publication date
US20100063075A1 (en) 2010-03-11
PT1585521E (pt) 2008-09-30
EP1585521B8 (en) 2009-03-25
BR0316877A (pt) 2005-10-25
GB0230015D0 (en) 2003-01-29
MY152921A (en) 2014-12-15
TWI333952B (en) 2010-12-01
AU2003296710B2 (en) 2007-11-15
TW200424196A (en) 2004-11-16
ZA200504386B (en) 2009-07-29
PE20040971A1 (es) 2005-01-12
AU2003296710A1 (en) 2004-07-14
WO2004056365A2 (en) 2004-07-08
EP1585521A2 (en) 2005-10-19
EP1844780A2 (en) 2007-10-17
DE60321722D1 (de) 2008-07-31
JP4485956B2 (ja) 2010-06-23
NO20053498L (no) 2005-07-18
WO2004056365A3 (en) 2004-08-19
ECSP055888A (es) 2005-09-20
NO331845B1 (no) 2012-04-23
NZ540849A (en) 2008-08-29
JP2006516247A (ja) 2006-06-29
ES2308041T3 (es) 2008-12-01
KR20070097136A (ko) 2007-10-02
PL378916A1 (pl) 2006-05-29
AR042650A1 (es) 2005-06-29
EP1585521B1 (en) 2008-06-18
IL169183A0 (en) 2009-02-11
US20060079685A1 (en) 2006-04-13
US7696216B2 (en) 2010-04-13
IL169183A (en) 2011-11-30
CN1732002A (zh) 2006-02-08
EP1844780A3 (en) 2008-03-05
CA2509151A1 (en) 2004-07-08
ATE398450T1 (de) 2008-07-15
JP2010159258A (ja) 2010-07-22
US8569317B2 (en) 2013-10-29
KR100801348B1 (ko) 2008-02-11
CA2509151C (en) 2011-11-22
RU2005123329A (ru) 2006-03-10
CN101445486A (zh) 2009-06-03
KR20050094822A (ko) 2005-09-28
MXPA05006866A (es) 2005-08-16
HK1084043A1 (en) 2006-07-21

Similar Documents

Publication Publication Date Title
RU2358972C2 (ru) Производные арилхиназолина, которые способствуют высвобождению паратиреоидного гормона
RU2436780C2 (ru) Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы
RU2439068C2 (ru) Модуляторы mglur5
RU2437882C2 (ru) Производные имидазолидинона
JP2006512357A5 (ru)
JP2005532371A5 (ru)
RU2005102002A (ru) Новые производные тетрагидропиридина
RU96111418A (ru) ПРОИЗВОДНЫЕ ПИРИМИДИНДИОНА, ПИРИМИДИНТРИОНА, ТРИАЗИНДИОНА, ТЕТРАГИДРОХИНАЗОЛИНДИОНА В КАЧЕСТВЕ АНТАГОНИСТОВ α1 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ
JP2004534824A5 (ru)
RU2008141509A (ru) Mglur5 модуляторы 1
JP2006513265A5 (ru)
PE20011114A1 (es) Decahidro-isoquinolinas
RU2009125019A (ru) Производные карбоновой кислоты
CN1859903A (zh) Ep2选择性受体激动剂在药物治疗中的应用
MA29148B1 (fr) Derives de pyrazole condenses, et procedes pour traiter des troubles lies au metabolisme
NZ614305A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
NZ588652A (en) Carboxamide compounds for the treatment of metabolic disorders
JP2005528361A5 (ru)
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
RU2011100781A (ru) 2-пиридил-замещенные имидазолы в качестве ингибиторов alk5 и/или alk4
FR2814678A1 (fr) Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
JP2004523535A5 (ru)
JP2002053555A5 (ru)
CA2624602A1 (en) Process for preparing 6-substituted-7-azaindoles
PE20060121A1 (es) Compuestos amidas biciclicos como antagonistas del receptor de acetilcolina muscarinico m3

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20151223